


How to find us



Event location

Bayerische Landesärztekammer (BLÄK)/
State Chamber of Physicians of Bavaria
Mühlbauerstraße 16
81677 Munich, Germany

Registration

Please register to participate by 17 April 2024 at:
www.leopoldina.org/registration-vulnerable-people/

The Leopoldina originated in 1652 as a classical scholarly society and now has 1,600 members from almost all branches of science. In 2008, the Leopoldina was appointed as the German National Academy of Sciences and, in this capacity, was invested with two major objectives: representing the German scientific community internationally, and providing policymakers and the public with science-based advice.

The Leopoldina champions the freedom and appreciation of science. It promotes a scientifically enlightened society and the responsible application of scientific insight for the benefit of humankind and the natural world. In its interdisciplinary discourse, the Academy transcends thematic, political and cultural boundaries. It is also an advocate of human rights.



Leopoldina
Nationale Akademie
der Wissenschaften

Research with vulnerable people

A targeted interdisciplinary discussion within the
scope of the WMA Declaration of Helsinki revision

Contact

German National Academy of Sciences Leopoldina
Dr. Stefanie Bohley, E-Mail: stefanie.bohley@leopoldina.org
German Medical Association
Dr. Ramin Parsa-Parsi, E-Mail: international@baek.de

14 – 15 May 2024

State Chamber of Physicians of Bavaria (BLÄK)
Mühlbauerstraße 16
81677 Munich, Germany

In collaboration with



With kind support of



Research with vulnerable people

A targeted interdisciplinary discussion within the scope of the WMA Declaration of Helsinki revision

In July 2023, the German National Academy of Sciences Leopoldina established a working group focused on the Framework Conditions for Clinical Trials on Vulnerable People. The objective of the working group is to demonstrate ethically justified improvements to the framework conditions for clinical studies on vulnerable people, particularly children and adolescents.

Co-organised by the Leopoldina and the German Medical Association, in collaboration with the World Medical Association and the American Medical Association, and with kind support from the State Chamber of Physicians of Bavaria, the conference “Research with vulnerable people” represents one aspect of the working group’s approach. This targeted interdisciplinary discussion will be held within the scope of the ongoing revision of the World Medical Association’s Declaration of Helsinki (DoH). The aim of this meeting is to foster discussion on the paragraphs in the DoH focused on vulnerability with proven experts and then to proactively contribute the resulting findings to the revision process.

Day 1 – 14 May 2024

12:00 – 01:00 pm | Lunch for all participants

12:00 – 02:00 pm | On-site registration

02:00 – 02:30 pm

Welcome remarks

Gerald Quitterer, MD, President, Bavarian State Chamber of Physicians

Representative of the (Bavarian) government (tbc)

Lujain AlQodmani, MD, WMA President

Gerald Haug, PhD, President, Leopoldina

Klaus Reinhardt, MD, President, German Medical Association

02:30 – 02:45 pm

Brief introduction and history of the WMA Declaration of Helsinki

Ramin Parsa-Parsi

MD, MPH, Head of Department for International Affairs, German Medical Association

02:45 – 03:00 pm

Introduction to the current DoH revision process and recap of previous WMA conferences on vulnerable groups

Jack Resneck

MD, Chair of WMA DoH Workgroup

03:00 – 03:15 pm

Introduction to the current discussion in the Leopoldina workgroup

Urban Wiesing ML

MD, PhD, Chair of Leopoldina WG on vulnerable groups

03:15 – 03:45 pm

Mapping of vulnerability

Pierre Mermet-Bouvier

PhD, Senior Manager, eCOA, ICON, Paris

03:45 – 04:00 pm | Coffee break

04:00 – 05:00 pm

Analysis of vulnerability

Samia Hurst

MD, Director, Institute for Ethics, History, and the Humanities, University of Geneva

Vulnerability in different research settings

Florencia Luna

PhD, Principal Researcher, FLACSO/CONICET, Buenos Aires

Vulnerability as defined in the CIOMS guidelines

Rieke van der Graaf

PhD, Julius Center, Department of Global Public Health & Bioethics, UMC Utrecht

Hilary Marston

M.D., M.P.H., Chief Medical Officer (CMO) of the US Food and Drug Administration

05:00 – 05:45 pm

Panel discussion

Panel: Drs. Mermet-Bouvier, Hurst, Luna, van der Graaf

Moderator: Steinunn Þórðardóttir

MD, Chair, WMA Medical Ethics Committee

06:00 pm | Dinner

Day 2 – 15 May 2024

09:00 – 10:30 am

Delay of medicines, focus on children

Gilles Vassal

PhD, Gustave Roussy Comprehensive Cancer Center, Paris

Children, subsidiarity of research

Olaf Witt

MD, University Hospital Heidelberg

Conditions under which research with vulnerable groups should be permitted + Discussion

Alex John London

PhD, Director, Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh

Adam C. Berger, PhD

Director, Division of Clinical and Healthcare Research Policy, Office of Science Policy, Office of the Director | US National Institutes of Health

10:30 – 11:00 am | Coffee break

11:00 am – 12:30 pm

Panel discussion and review of the WMA DoH paragraph on vulnerable groups

Panel: Drs. Vassal, Witt, London, Wiesing

Moderator: Jack Resneck

MD, Chair of WMA DoH workgroup

12:30 – 01:30 pm | Lunch for all participants

End of meeting

02:00 – 04:00 pm

Closed WMA DoH workgroup meeting incl. selected guests

04:00 – 06:00 pm | Tour of Munich

(for all participants who registered for the tour)

06:00 pm | Informal dinner

(for all participants who registered for the dinner)